The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS)
Abstract
Purpose: In experimental systems, interference with coagulation can affect tumor biology. Furthermore, it has been suggested that low molecular weight heparin therapy may prolong survival in patients with cancer. The primary aim of this study was to assess survival at 1 year of patients with advanced cancer. Patients and Methods: Patients with advanced malignancy (N = 385) were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year. Results: The Kaplan-Meier survival estimates at 1, 2, and 3 years after randomization for patients receiving dalteparin were 46%, 27%, and 21%, respectively, compared with 41%, 18%, and 12%, respectively, for patients receiving placebo (P = .19). In an analysis not specified a priori, survival was examined in a subgroup of patients (dalteparin, n = 55; and placebo, n = 47) who had a better prognosis and who were alive 17 months after randomization. In these patients, Kaplan-Meier survival estimates at 2 and 3 years from randomization were significantly improved for patients receiving dalteparin versus placebo (78% v 55% and 60% v 36%, respectively, P = .03). The rates of symptomatic venous thromboembolism were 2.4% and 3.3% for dalteparin and placebo, respectively, with bleeding rates of 4.7% and 2.7%, respectively. Conclusion: Dalteparin administration did not significantly improve 1-year survival rates in patients with advanced malignancy. However, the observed improved survival in a subgroup of patients with a better prognosis suggests a potential modifying effect of dalteparin on tumor biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirsh, J., Warkentin, T. E., Shaughnessy, S. G., Anand, S. S., Halperin, J. L., Raschke, R., Granger, C., Ohman, E. M., & Dalen, J. E. (2001) · Chest · doi:10.1378/chest.119.1_suppl.64s · Cited by 1,580
Hirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Self-citationHeparin and heparan sulfate: Structure and function
Rabenstein, D. L. (2002) · Natural Product Reports · doi:10.1039/b100916h · Cited by 870
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649
Gould, M. K., Dembitzer, A. D., Doyle, R. L., Hastie, T. J., & Garber, A. M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-10-199905180-00003 · Cited by 627
Managing Oral Anticoagulant Therapy
Ansell, J., Hirsh, J., Dalen, J., Bussey, H., Anderson, D., Poller, L., Jacobson, A., Deykin, D., & Matchar, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.22s · Cited by 572
Levine, M., Hirsh, J., Arnold, A., Gent, M., Levine, M., Arnold, A., Bramwell, V., Pritchard, K. I., Stewart, D., Warr, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90008-6 · Cited by 510
Self-citationSiragusa, S., Cosmi, B., Piovella, F., Hirsh, J., & Ginsberg, J. S. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89484-3 · Cited by 373
Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, A. J., Edwards, R. L., Headley, E., Kim, S.-H., O'Donnell, J. F., et al. (1984) · Cancer · doi:10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f · Cited by 343
Incidence of Cancer after Prophylaxis with Warfarin against Recurrent Venous Thromboembolism
Schulman, S., & Lindmarker, P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422604 · Cited by 326
Subcutaneous heparin treatment increases survival in small cell lung cancer
Lebeau, B., Chastang, C., Brechot, J.-M., Capron, F., Dautzenberg, B., Delaisements, C., Mornet, M., Brun, J., Hurdebourcq, J.-P., & Lemarie, E. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e · Cited by 277
Do Heparins Do More than Just Treat Thrombosis? The Influence of Heparins on Cancer Spread
Hettiarachchi, R., Smorenburg, S., Ginsberg, J., Levine, M., Prins, M., & Büller, H. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615937 · Cited by 206
Self-citationExtrinsic-pathway activation in cancer with high factor Vlla and tissue factor
Kakkar, A. K., DeRuvo, N., Chinswangwatanakul, V., Tebbutt, S., & Williamson, R. C. N. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91690-3 · Cited by 199
Self-citationLower mortality in cancer patients treated with low-molecular-weight versus standard heparin
Green, D., Hull, R., Brant, R., & Pineo, G. (1992) · The Lancet · doi:10.1016/0140-6736(92)92064-m · Cited by 165
Tissue factor in cancer angiogenesis and metastasis
Ruf, W., & Mueller, B. M. (1996) · Current Opinion in Hematology · doi:10.1097/00062752-199603050-00008 · Cited by 136
Coagulation proteases and human cancer
Sampson, M. T., & Kakkar, A. K. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300201 · Cited by 75
Self-citation8 Venous thromboembolism and cancer
Kakkar, A. K., Lorenzo, F., Pineo, G. F., & Williamson, R. C. (1998) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(98)80089-9 · Cited by 40
Self-citationAntithrombotic therapy in cancer
Kakkar, A. K., & Williamson, R. C. (1999) · BMJ · doi:10.1136/bmj.318.7198.1571 · Cited by 37
Self-citation
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Prevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Torbicki, A., Perrier, A., Konstantinides, S., Agnelli, G., Galiè, N., Pruszczyk, P., Bengel, F., Brady, A. J. B., Ferreira, D., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn310 · Cited by 2,826
Incidence of Venous Thromboembolism and Its Effect on Survival Among Patients With Common Cancers
Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., & White, R. H. R. (2006) · Archives of Internal Medicine · doi:10.1001/.458 · Cited by 1,321
Metadata
- Authors
- Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., & Williamson, R. C. N.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-05-15
- Volume
- 22
- Issue
- 10
- Pages
- 1944-1948
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2142386661
- Cited by
- 650
- References
- 19
- FWCI
- 34.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.